Sanofi, Regeneron: Dupixent shows Remission of Eosinophilic Esophagitis in kids in Phase 3

 A majority of children on Dupixent (up to 68% on a higher dose) achieved histological disease remission at week 16

First and only Phase 3 trial to show positive results in this patient population; there are currently no approved treatments specifically indicated for children under 12 years of age with EoE

https://finance.yahoo.com/news/dupixent-dupilumab-breaking-phase-3-045900407.html